BKBarbora Hrcka Krausova

Barbora Hrcka Krausova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Barbora Hrcka Krausova has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mice carrying a GluN2B protein-truncating variant have altered NMDA receptor subunit composition and their behavior recapitulates patient phenotypes

    by Klevinda Fili, Viktor Kuchtiak, Eni Tomovic, Miriam Candelas Serra, Agnieszka Kubik-Zahorodna, Karel Harant, Paulina Bozikova, Jiri Cerny, Miloslav Korinek, Barbora Hrcka Krausova, et al.

    Pathogenic variants in GRIN2B , encoding the NMDA receptor (NMDAR) GluN2B subunit, are linked to intellectual disability (ID) and related neurodevelopmental disorders. While most disease-associated variants are missense, protein-truncating variants (PTVs) may cause haploinsufficiency with less severe phenotypes. Here, we characterize a knock-in mouse model carrying the GluN2B-L825Ffs*15 PTV ( Grin2b +/Δ ). Proteomic analysis revealed markedly reduced full-length GluN2B protein and no detectable truncated GluN2B, accompanied by a small compensatory increase in GluN2A. Electrophysiology in hippocampal neurons demonstrated reduced NMDA-induced currents, diminished ifenprodil sensitivity, and accelerated NMDAR-mediated EPSC deactivation, consistent with a shift toward GluN2A-containing receptors. AMPAR-mEPSC amplitudes were increased, indicating altered excitatory synaptic function. Behaviorally, Grin2b +/Δ mice exhibited hypoactivity, increased anxiety in males, and impaired sensorimotor gating in both sexes, while learning, memory, and social behaviors remained largely intact. These results demonstrate that a monoallelic GluN2B PTV alters NMDAR subunit composition and function, producing moderate behavioral effects, and provide insight into mechanisms underlying GRIN2B -associated ID.


  • Open Access

    Phenotype of mice carrying an NMDA receptor GluN2B protein-truncating variant associated with intellectual disability

    by Klevinda Fili, Viktor Kuchtiak, Eni Tomovic, Miriam Candelas Serra, Agnieszka Kubik-Zahorodna, Karel Harant, Paulina Bozikova, Jiri Cerny, Miloslav Korinek, Barbora Hrcka Krausova, et al.

    Pathogenic variants in GRIN2B , encoding the NMDA receptor (NMDAR) GluN2B subunit, are linked to intellectual disability (ID) and related neurodevelopmental disorders. While most disease-associated variants are missense, protein-truncating variants (PTVs) may cause haploinsufficiency with less severe phenotypes. Here, we characterize a knock-in mouse model carrying the GluN2B-L825Ffs*15 PTV ( Grin2b +/Δ ). Proteomic analysis revealed markedly reduced full-length GluN2B protein and no detectable truncated GluN2B, accompanied by a compensatory increase in GluN2A. Electrophysiology in hippocampal neurons demonstrated reduced NMDA-induced currents, diminished ifenprodil sensitivity, and accelerated NMDAR-mediated EPSC deactivation, consistent with a shift toward GluN2A-containing receptors. AMPAR-mEPSC amplitudes were increased, indicating altered excitatory synaptic function. Behaviorally, Grin2b +/Δ mice exhibited hypoactivity, increased anxiety in males, and impaired sensorimotor gating in both sexes, while learning, memory, and social behaviors remained largely intact. These results demonstrate that a monoallelic GluN2B PTV alters NMDAR subunit composition and function, producing moderate behavioral effects, and provide insight into mechanisms underlying GRIN2B -associated ID.

  • Open Access

    Positive Modulators of N -Methyl- D -Aspartate Receptor: Structure-Activity Relationship Study on Steroidal C-17 and C-20 Oxime Ethers

    by Santosh Kumar Adla, Barbora Hrcka Krausová, Bohdan Kysilov, Karel Kudláček, Radko Souček, Miloš Budešínský, Jan VoldřIch, Ladislav Vyklický, Eva Kudová

    N -methyl-D-aspartate receptors (NMDARs) are crucial therapeutic targets, modulated by endogenous neurosteroids like pregnenolone sulfate ( PES ). This study investigates a novel structure-activity relationship approach focusing on the steroidal D-ring, employing the bioisosteric replacement of C-17 or C-20 keto groups with oximes and oxime ethers. We synthesized a series of pregn-5-ene and androst-5-ene derivatives ( 11 – 23 ) and evaluated their positive allosteric modulator (PAM) activity on recombinant rat GluN1/GluN2B receptors via patch-clamp in HEK293 cells. Our study revealed that pregnenolone-derived C-20 oxime ethers are potent and efficacious PAMs of NMDAR. Several analogues have been demonstrated as more potent than PES (E max = 116%; EC 50 = 21.7 µM). Compound 12 (C-20 ethyl oxime ether, C-3 hemiglutarate) displayed the highest efficacy, potentiating NMDAR currents over 6-fold more than PES (E max = 673 ± 121%; EC 50 = 8.7 ± 1.1 µM). Compound 17 (C-20 methyl oxime ether analogue) exhibited the highest potency, being over 3.5-fold more potent than PES (E max = 503 ± 68%; EC 50 = 6.1 ± 0.4 µM). In contrast, some C-17 analogues and derivatives with bulkier C-20 oxime substituents showed complex modulatory behavior. Promisingly, key compounds demonstrated favorable in vitro ADME profiles, including high metabolic stability and, for 12 , excellent thermodynamic solubility. These results validate C-20 oxime ether modification of the pregnenolone scaffold as an effective strategy for generating potent NMDAR PAMs with potentially superior efficacy and drug-like properties compared to endogenous modulators.

  • Open Access

    Disruption of grin2A , an epilepsy-associated gene, produces altered spontaneous swim behavior in zebrafish

    by Vera Abramova, Eni Tomovic, Bohdan Kysilov, Miloslav Korinek, Mark Dobrovolski, Barbora Hrcka Krausova, Klevinda Fili, Fatma Elzahraa S. Abdel Rahman, Paulina Bozikova, Jiri Cerny, et al.

    N-methyl-D-aspartate receptors (NMDARs) control synaptic plasticity and brain development in a manner determined by receptor subunit composition. Pathogenic variants in GRIN2A gene, encoding the NMDAR GluN2A subunit, can cause gain or loss of function of receptors containing the affected subunit, and are associated with intellectual disability and epilepsy in patients. While in-vitro studies of recombinant receptors have yielded some insights, animal experimental models are essential to better understand the relationship between the molecular pathology of the variants and the disease. Here we introduce a zebrafish model of GluN2A loss of function to study system-level effects of zebrafish grin2Aa and grin2Ab gene deletion. Our electrophysiological analysis revealed functional differences between receptors containing zebrafish GluN2Aa/b and GluN2Bb paralogs comparable to mammalian receptors containing GluN2A vs. GluN2B subunits. Both grin2Aa −/− and grin2Ab −/− , as well as double-knockout grin2A −/− zebrafish larvae showed increased locomotor activity in a novel environment. Proteomic analysis suggested that the relative proportion of GluN2B-containing NMDARs may be increased in grin2A mutant fish. Our results highlight fundamental similarities between zebrafish and mammalian NMDAR signaling and validate the use of zebrafish as a model organism to study the neurodevelopmental role of NMDARs. The newly created transgenic zebrafish strains complement the rodent models of GluN2A loss of function and can be used for high-throughput testing of pharmacological or genetic treatment strategies for patients with GRIN2A gene variants.

  • Open Access

    Disease-associated nonsense and frame-shift variants resulting in the truncation of the GluN2A or GluN2B C-terminal domain decrease NMDAR surface expression and reduce potentiating effects of neurosteroids

    by Bohdan Kysilov, Viktor Kuchtiak, Barbora Hrcka Krausova, Ales Balik, Miloslav Korinek, Klevinda Fili, Mark Dobrovolski, Vera Abramova, Hana Chodounska, Eva Kudova, et al.

    N-methyl-d-aspartate receptors (NMDARs) play a critical role in normal brain function, and variants in genes encoding NMDAR subunits have been described in individuals with various neuropsychiatric disorders. We have used whole-cell patch-clamp electrophysiology, fluorescence microscopy and in-silico modeling to explore the functional consequences of disease-associated nonsense and frame-shift variants resulting in the truncation of GluN2A or GluN2B C-terminal domain (CTD). This study characterizes variant NMDARs and shows their reduced surface expression and synaptic localization, altered agonist affinity, increased desensitization, and reduced probability of channel opening. We also show that naturally occurring and synthetic steroids pregnenolone sulfate and epipregnanolone butanoic acid, respectively, enhance NMDAR function in a way that is dependent on the length of the truncated CTD and, further, is steroid-specific, GluN2A/B subunit-specific, and GluN1 splice variant-specific. Adding to the previously described effects of disease-associated NMDAR variants on the receptor biogenesis and function, our results improve the understanding of the molecular consequences of NMDAR CTD truncations and provide an opportunity for the development of new therapeutic neurosteroid-based ligands.


  • Specific pathogenic mutations in the M3 domain of the GluN1 subunit regulate the surface delivery and pharmacological sensitivity of NMDA receptors

    by Marharyta Kolcheva, Stepan Kortus, Barbora Hrcka Krausova, Petra Barackova, Anna Misiachna, Sarka Danacikova, Martina Kaniakova, Katarina Hemelikova, Matej Hotovec, Kristyna Rehakova, et al.


  • 7-phenoxytacrine is a dually acting drug with neuroprotective efficacy in vivo

    by Martina Kaniakova, Jan Korabecny, Kristina Holubova, Lenka Kleteckova, Marketa Chvojkova, Kristina Hakenova, Lukas Prchal, Martin Novak, Rafael Dolezal, Vendula Hepnarova, et al.